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CHAPTER 1
INTRODUCTION
I. Experimental autoimmune thyroiditis
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thyroiditis (HT), an organ-specific, T cell-mediated autoimmune disorder of humans (1). The
prevalence rate of this hypothyroid syndrome is 8/1000 in the US population (2). G

es’ d se se

or hyperthyroidism is also widely prevalent in the US population. Hypothyroidism is more
common in women compared to men (3). In a study conducted in USA, subclinical thyroiditis
was observed in 4.6% of the population (4,5). As is evident from the data, HT affects a
substantial number of individuals in the population and, many of whom are not even diagnosed
as having the disease (6-8). It is therefore important to study the disease in order to understand
the various predisposing factors and also the mechanism of disease development. Rose et al. (911) immunized dogs, rabbits and guinea pigs with homologous and heterologous thyroid extracts
nc

lete F eund’s dju nt, w c

esulted n t y

d t s nd utoantibody production. Later

work in our laboratory with self antigen, mouse thyroglobulin (mTg) in mice, by immunization
alone without adjuvant demonstrated the existence of autoreactive T cells which could be primed
and activated to produce autoimmune thyroiditis (12). Some earlier models of EAT also included
the use of rat and chicken (13). Because of the ease of manipulation and the wide range of strains
and reagents, making it easier to study the immunogenetics and pathogenic mechanisms of the
disease, the murine model has become the most important.
The major histocompatibility complex (MHC) plays an important role in defining
susceptibility to autoimmune disorders. The peptide-binding groove of MHC molecules contains
variable regions and this genetic polymorphism determines the specificity and affinity of peptide
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binding and T cell recognition. For HT, the association with human leukocyte antigen (HLA)
complex has been studied in patient populations and genetic susceptibility has been associated
with the HLA-DRA/DRB1*03:01 (HLA-DR3) allele, HLA- DRB1*04:05 (HLA-DR4), HLADRB1*11/*12 (HLA-DR5) in Caucasians. The mouse H2 class II genes are very similar to the
HLA class II region in defining susceptibility in multiple autoimmune disorders (14). In
particular, murine EAT has been very valuable in pinpointing the HLA class II association in HT
using transgenic mice (15-17). For example, the introduction of HLA-DR and DQ genes into
mouse MHC class II knockout mice demonstrated that HLA-DR3 is the susceptibility allele for
EAT (18) and that HLADQ*03:01/DQB1*03:02 (HLA-DQ8) molecules can downmodulate
DR3-mediated thyroiditis (19).
For murine EAT, susceptibility has been mapped to the H2 k and s haplotypes, while the
b and d haplotypes are resistant (20). The k haplotype strain CBA/J is used in our lab. In the
CBA/J strain, females are somewhat more susceptible to the disease compared to males. In the
H2 complex, susceptibility has been narrowed to the class II subregion, especially the IA
subregion (21).
The disease is induced in mice by immunization with 40 µg of mTg intravenously (iv),
followed by 20 µg of Salmonella enteritidis lipopolysaccharide (LPS) 3 hrs later. These
injections are repeated after 7 days and EAT is usually evaluated 3 weeks later (22). After
immunization, the readout for EAT is T cell proliferation to mTg in vitro, mTg autoantibody
levels and thyroid pathology. The self-reactive T cells, both CD4+ and CD8+, as well as
macrophages, traffic to the thyroid and cause the destruction of the follicles. The extent of
thyroid infiltration is determined by examining histologic sections. Since LPS induces the
production of IL-1 in vivo (23), immunomodulatory IL-1 cytokine can also be used as a T cell
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adjuvant to induce EAT. This protocol involves using 20 µg mTg followed 3 hrs later with
varying doses of IL-1 (24). The injections are repeated after 7 days and the mice sacrificed 3
weeks later to examine thyroid pathology. In our EAT model, repeated injections of 40 µg mTg
can also induce autoimmunity without the need for adjuvant in a susceptible strain (12). The
induced disease with repeated injections of soluble self antigen can be exacerbated by depletion
of CD4+CD25+Foxp3+ regulatory T cells (Tregs) prior to the induction process (25).
The kinetics of mononuclear cell infiltration into the thyroid were investigated by
immunochemical analysis (26). The ratio of CD4+ and CD8+ T cells increased from 2.4 on day
21 to 3.0 on day 42. The experiment therefore clearly indicated the early importance of CD4 + T
cells which recruited macrophages for thyroid infiltration and destruction. The CD8+ T cells that
followed are also involved in thyroid pathology as evidenced by their cytotoxic destruction in
vitro of thyroid monolayer (27).
In spite of having susceptible HLA alleles and autoreactive T cells, not all susceptible
humans and animals develop autoimmunity. This self resistance against the manifestation of
autoimmunity is important in control of onset of disease in susceptible individuals as well as in
individuals where the disease process has already started.
II. Tolerance in EAT
Natural self resistance against autoimmunity is called tolerance. Tolerance helps in
discriminating between self and non-self. It is achieved by two processes: 1) Central tolerancewhere high affinity autoreactive T cells are eliminated in the thymus; and 2) peripheral tolerancewhere autoreactive T cells against self antigens are actively suppressed (28-30). Central
tolerance not only involves deletion of autoreactive T cells but also the selection of Tregs. The
Treg population helps in maintaining T cell tolerance in autoreactive T cells which have escaped
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central tolerance, and contributes towards peripheral tolerance (28,31). It was earlier believed
that natural tolerance to EAT in genetically susceptible, nonimmunized mice was due to
sequestration of antigen or antigen which is not released into the circulation in the host. As a
result the autoreactive T cells could not react as they did not see the antigen. In experiments
shown by Kong et al. in 1982 (32), this notion was not sustainable. They also challenged that
autoimmunity is not due to lack of suppressor T cells (Tregs) as these cells exist in susceptible
mice. Subsequent studies showed that several protocols can strengthen tolerance against
induction of EAT: 1) Bovine thyroid-stimulating hormone (TSH) infusion via mini-osmotic
pumps placed in the peritoneal cavity (33,34); 2) high dose tolerance with two doses of 100 µg
of deaggregated mTg (dmTg), 7 days apart; 3) daily low dose of 10 µg mTg for 10 days (33);
and 4) LPS, which interferes with the kinetics of mTg clearance, given 24 hrs before mTg (34).
Tolerance induction by all four protocols was shown to correlate with raised, circulatory mTg for
2-3 days (33,34).
The cells mediating tolerance were first identified as Thy-1+ T cells (32). With the
advances of monoclonal antibody (mAb) technology, rat IgG2b monoclonal antibodies (mAbs)
against mouse L3T4+ (CD4+) and Lyt2+ (CD8+) T cells were used in depletion studies (35). The
data showed that CD4+ T cells were responsible for the induced tolerance with mTg and
tolerance was abrogated when these cells were depleted. Thus tolerance mechanisms involve
active suppression that requires the constant presence of Tregs. Other experiments,
subtolerogenic doses of dmTg along with gamma-

d ted s leen cells (γSC) t en f

T -

primed mice were found to inhibit the induction of EAT (36). It was interesting to note that this
syne

st c su

ess n w s effect e nly w en d T w s

en bef e γSC, suggesting that

suppression was dependent on initial activation of regulatory CD4+ T cells. The difference
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between using dmTg alone (32) nd dd n γSC w s t e

t nce of CD8+ Tregs in the second

protocol (36), as CD4+ Tregs were activated first in order to suppress EAT induction. As to the
duration of tolerance, this was tested by challenging with mTg and LPS at intervals after
pretreatment with dmTg, two doses 7 days apart. Significant decrease in mTg antibody titers and
thyroid infiltration was observed beginning 10 days to 94 days after pretreatment (37). The
duration of tolerance was similar when either dmTg or TSH infusion was used for tolerance
induction (37).
The contribution of cytokines to the tolerant status was next examined. Human
recombinant IL-1β (IL-1β),

-inflammatory cytokine, given at 4000U. 3 hrs after the

injection of mTg, inhibited the induction of tolerance and the animals developed EAT upon
challenge with mTg plus LPS (24). However, the timing of IL-1β d
in inhibiting the establishment of tolerance. IL-1β

en 1

n st t n w s

2 d ys fte d T

t nt

et e t ent

failed to inhibit tolerance induction to EAT. Similar to the use of LPS in the challenge, IL-1β
was unable to abrogate suppression in animals already tolerized with dmTg. Next, the role of IL12 was examined (38). IL-12 along with dmTg primed the autoreactive T cells and converted
tolerogenic dmTg into an immunogen. As was shown with IL-1, the timing of IL-12 injection
along with dmTg was important. On the other hand, IL-4 and IL-10 were found to have minimal
or no role in EAT tolerance induction (39).
Sakaguchi et al. (40) investigated the mechanisms of peripheral tolerance and found that
it was mediated by CD4+CD25+ Tregs in naive mice. Thus CD25 (IL-2R α c

n) bec

es an

additional marker for Tregs. This Treg population constitutes about 10% of the peripheral CD4 +
cells. When the CD4+ population was depleted of CD4+CD25+ Tregs and transferred into
BALB/c athymic nude mice, spontaneous multiorgan autoimmunity developed. Thus, as we
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discussed earlier (32,35), peripheral tolerance is actively maintained in the periphery by Tregs
which keep the self-reactive clones of T cells in check. Subsequently, Hori et al., (41) examined
scurfin mutant mice that express a multiorgan lymphoproliferative disorder. It was found that a
forkhead transcription factor Foxp3 was lacking, and that this gene was expressed more in the
CD4+CD25+ Treg population. To date, Foxp3 is the most specific marker available for Tregs.
To define the importance of CD4+CD25+ Tregs in induced tolerance to EAT, Morris et
al.(42) depleted CD4+CD25+ Tregs with CD25 mAb and abrogated the established tolerance,
again demonstrating its importance in EAT. Moreover, tolerance cannot be induced without the
presence of this Treg subset (25).
Tolerance mechanisms in EAT were studied in recent years with the aid of the CD25
marker for Treg isolation. Several costimulatory molecules were examined. CD137 is a member
of the tumor-necrosis factor receptor superfamily and is found on activated B and T cells,
activated NK cells, DCs (43,44). CD137 is known to interact with 4-1BB ligand and is involved
in lymphocyte survival, costimulation and enhancement of effector function. Morris et al. (42)
observed that anti-CD137 given 2 hrs prior to the injection of dmTg inhibited the induction of
tolerance. CD137 mAb was found to partially abrogate established tolerance in vivo in mice. The
effect on established tolerance was also demonstrated in vitro, when CD137 mAb inhibited the
suppression by CD4+CD25+ Tregs. The cell target of CD137 mAb appeared to be mTg-primed T
cells, where the anti-CD137 agonistic role increased the proliferative response.
Glucocorticoid-induced tumor necrosis factor receptor (GITR) was next examined for
its immunomodulatory role on Tregs and tolerance (45). Injection of GITR mAb also interfered
with tolerance induction by dmTg and converted its role from a tolerogen to an immunogen,
since thyroiditis resulted without subsequent EAT induction. This conversion was reminiscent of
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IL-1 and IL-12 action in providing a priming stimulus (24,46). For comparative purposes, in
EAT, IL-1 and anti-GITR are the stronger autoimmune stimuli than IL-12 and anti-CD137.
In a similar manner, administration of CTLA-4 mAb with dmTg interfered with
tolerance induction, indicating the important role of CTLA-4 as a marker for Treg function.
However, once the mTg autoreactive T cells had been primed, the presence of CTLA-4 mAb was
no longer effective; it did not inhibit the suppressive action of Tregs in vitro on mTg-primed T
cells (25).
III. Clinical problem: increased autoimmunity while boosting anti-tumor immune response
Combination of surgery, radiation and chemotherapy are the current treatment strategies
for tumor (47). Since these treatment modalities are non-specific and impose many side effects
along with recurrences due to incomplete removal of tumor, there has been increased focus on
immunotherapeutic strategies targeting the tumor or immune network. Tumor immunotherapy
provides either passive or active immunity against tumors (48). Active immunotherapy involves
harnessing the immune system by vaccination with tumor-associated antigens, or just tumor
antigens, to induce or expand antigen-specific T cells (47). Passive immunotherapy includes
many immunologic agents made outside of the host. Some sources of tumor antigens are:
products of oncogenic viruses and products of oncogenes or mutated oncosuppressors (49).
Tumor antigens are shared antigens between cancer cells and normal cells and may differ in
terms of expression (50).
Tumors are known to suppress and evade the immune response using various
immunosuppressive factors such as TGF-β, den s ne,

st l nd ns E2,

n l s des (50,51).

The immunosuppressive effect may be directed toward a tumor-specific response or it might be
local or systemic immunosuppression. Tumors are also known to actively recruit and accumulate
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Tregs or more specifically induced Tregs (iTregs) (52-54). This generalized immunosuppression
or iTreg activation is one of the many reasons responsible for lack of good immune response
against tumors (55,56).
As we discussed in the previous sections, autoimmune thyroid disease in animals can be
generated by breaking tolerance using various protocols such as self antigen, heterologous
antigen (15), or DNA (57), with or without adjuvant and Th1 cytokines to prime T cells. In a
similar fashion, antigen-specific, anti-tumor responses can be generated by breaking tolerance
using tumor antigens and Th1 cytokines (58), or heterologous antigens or DNA (59-61), wholecell vaccines (62), peptide vaccines (63,64) and recombinant protein vaccines (55,56). These
anti-tumor immune responses can be further enhanced by using immunomodulators. Some of
them are CTLA-4 mAbs (65), anti-vascular endothelial growth factor mAbs to block growth of
blood vessels (66)and heat shock protein antibodies (67,68).
Antigen-presenting cells (APCs) such as DCs capture tumor as well as self antigens
during anti-tumor immune responses, leading to priming of autoreactive T cells and autoimmune
sequelae associated with tumor immunotherapy (69). Immunotherapy must deal with many
obstacles: immune tolerance to tumor antigens, weak antigens, and immune evasion mechanisms
employed by growing tumors (70,71). Tolerance may be broken during an infection or tissue
damage providing costimulatory signals and cytokines to autoreactive T cell expansion,
increasing undesirable sequelae during tumor immunotherapy.
Autoimmune thyroiditis was reported in patients treated with IL-2 and
lymphokine- activated killer cells for metastatic melanoma (72). Interestingly, 5 of the 7 patients
having hypothyroidism had tumor regression, whereas only 5 of the 27 patients who were
euthyroid had evidence of tumor regression. The authors hypothesized that treatment regimen
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might be causing hypothyroidism by exacerbating pre-existing autoimmune thyroid condition
and is associated with favorable anti-tumor response.
There are cellular antigens overexpressed by tumors (73). One example is MART-1 in
melanoma (74). Any vaccination regimen targeting MART-1 could potentially lead to
autoimmune responses against melanocytes leading to vitiligo (75). In another report, treating
melanoma patients with vaccine and low dose IL-2 led to autoimmune toxicities such as vitiligo,
diabetes and autoimmune thyroiditis (76). Patients with head and neck cancers undergoing
radiation and chemotherapy also developed autoimmune thyroiditis or subclinical thyroiditis (77).
Subclinical hypothyroidism was evident by high TSH level but normal T4 levels which was
termed as compensated thyroid. The authors surmised that chemotherapy was sensitizing the
thyroid gland to radiation leading to destruction and subsequent thyroiditis.
Blansfield et al. (78) reported autoimmunity in melanoma patients treated with mAb
against CTLA-4. CTLA-4 mAb prevents the negative costimulatory signal to be delivered to the
activated T cells. Anti-CTLA-4 also inhibits the functioning of Tregs which have higher
expression of CTLA-4 on their surface than the activated T cells (25). Therefore using this
antibody not only will enhance the anti-tumor immune response but will also lead to generalized
autoimmunity.

The

autoimmune

manifestations,

including

diabetes,

hypophysitis,

hypothyroidism, were reported in 25% of the patients. Tuve et al. (79) used a tumor cell line TC1, which was transfected to stably express CTLA-4 antibody, to examine TC-1 tumor
progression in mice. In immunocompetent mice given CTLA-4 transfected TC-1 tumors,
majority of the tumors regressed completely, whereas tumors grew in SCID mice and CD8
knockout mice. The anti-tumor immune response was shown to correlate with IFN-γ-secreting
CD8+ T cells. The blockade by CTLA-4 was also combined with anti-CD25 Treg depletion and
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was found to enhance the tumor regression synergistically. There was complete absence of
accompanying autoimmunity with intratumoral CTLA-4 blockade with or without systemic Treg
depletion.
Interferon-α s
y cell leu e

nd

syste

c

dul t

s ’s s c

ex ce b te HT, ty e 1 d betes, G

s been used t t e t e t t s C

us nfect n,

(80). The treatment regimen is known to initiate or

es’ d se se nd syste

c lu us e yt e

t sus. In study n

hepatitis C virus infection, the prevalence of patients with hypothyroidism increased from 6.1%
to 17.2% (81). Female gender and the presence of thyroid peroxidase (TPO) antibodies were
considered to be risk factors in developing autoimmune hypothyroidism and could also lead to
exacerbation of clinical hypothyroidism or of subclinical hypothyroidism (82,83). Autoimmune
disorders, such as psoriasis, type 1 diabetes and systemic lupus erythematosus have also been
shown to arise during treatment of conditions such as renal cell carcinoma, bladder carcinoma,
s ’s s c

wt

nte fe n α (84). In an article by McNeel et al. (85), 2 out of the 15

subjects treated with E75 immunodominant HLA-A2- restricted epitope from HER-2/neu tumor
antigen as a vaccine and Flt-3 ligand as an adjuvant for prostate cancer developed elevated TSH
levels and hypothyroidism. Examining retrospectively, high anti-thyroid antibody titer was found
in at least one patient who developed hypothyroidism later which is consistent with the clinical
picture of pre-existing subclinical autoimmune hypothyroidism.
Human epidermal growth factor receptor-2 (HER-2) is a marker overexpressed or
amplified in approximately 20% of breast cancer (86). Since HER-2 was an attractive target for
treating breast cancers, trastuzumab or Herceptin, a humanized mAb against HER-2, was
developed with encouraging results (86). HER-2 is also expressed by heart muscles cells (71)
and cardiac dysfunction was observed in 13% of the patients being treated with paclitaxel, an
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antiproliferative agent, and trastuzumab compared to 3-7% in patients treated with trastuzumab
alone (86,87).
The reasons for autoimmune toxicities were also discussed in many articles. Some
authors have argued that autoimmune side effects are due to increased antibody levels from
triggering autoreactive B cell clones leading to autoimmunity (88). One article suggests that the
serum levels of B cell-activating factor be assessed as risk factor before initiation of interferon
therapy which might affect the development of thyroid autoimmune disorders (89,90). It was
suggested that long term treatment with IFN-α le ds t

nc e sed t y

d ut

un ty nd t s

phenomenon was reversible after withdrawal (90).
It is clear from these clinical reports that immunomodulation with cytokines, stimulatory
or blocking antibodies can have a broad effect on the immune system leading to different types
of sequelae, particularly autoimmune responses. Of these autoimmune side effects, thyroiditis
seems not to be associated with a particular type of therapy during many trials. One reason could
be that the vast population is afflicted from thyroiditis but is unaware of it (4.3% subclinical
hypothyroidism, according to national health and nutrition examination survey III) (5). The
disease was also higher in females than in males and more in whites compared to blacks (3). It
may also be correlated with the levels of autoantibodies both to thyroglobulin and thyroid
peroxidase, and more so with thyroid peroxidase antibodies.
IV. Autoimmunity-tumor models
In recent years, there have been efforts made to understand the mechanisms involved in
the interplay between tumor immunity and autoimmunity. Our lab and others are developing
combined models of tumor and autoimmunity in order to mimic the clinical scenarios and
understand the underlying mechanisms.
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Early studies in 1980 (91) in a methylcholanthrene-induced fibrosarcoma model in
BALB/c x C57BL/6F1 mice demonstrated that Tregs were derived from the thymus. The
immunity against the tumor was generated by injection of endotoxin (Salmonella enteritidis
lipopolysaccharide B) (92) and the cells from such animals were used to treat syngeneic
recipients. The transfer of primed spleen cells against the tumor caused regression in the
recipients which were devoid of T cells (thymectomized and whole body irradiated). The tumor
bearing hosts however acquired a state of immunological tolerance which was dependent on the
growth of the tumor. Excision of tumor however led to the emergence of tumor-specific immune
response which prevented further growth.
It is now acknowledged that Tregs can inhibit priming of the immune system against
tumor (93). Depletion of Tregs followed by vaccination against a poorly immunogenic B16
melanoma was shown to prime the immune system and induce a CD8+ T cell immune response.
The B16 melanoma in mice has also been used as a model of tumor and autoimmunity. In
this model, the immune response is against melanoma-associated antigens and a robust T cellmediated immune response can also react with melanocytes leading to destruction and vitiligo
(94,95). Since B16 tumor is poorly immunogenic, immunostimulatory regimens such as, altered
peptide vaccination with IL-2 could aid the overcoming of tolerance (95) .
CD8+ T cells are important in rejection against melanoma as demonstrated in CD4 and
CD8 knockout mice in C57BL/6 mice (96). Residual tumor cells in the host were important to
achieve concomitant tumor immunity which aids the rejection of secondary tumors at distant
sites. While it is known that CD8+ T cells play a protective role in the destruction of melanoma,
the role of CD4+ T cells is unclear. Some groups claimed that, in order to prime CD8+ T cells,
CD4+ T cells were not required and priming could take place in complete absence of CD4+ T
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cells as evidenced by depletion studies (94,97). Others showed the importance of CD4+ T cells in
the long-term protection (98).
Although a shared antigen as melanocyte in different organs is one part of the clinical
picture, the other part is the completely unrelated autoimmune side effects during tumor
immunotherapy. Our autoimmunity and tumor models represent the steps taken to address this
other question and to find out the reasons therein.
In order to study the effect of EAT on established tumor models, the first combined EATtumor model was developed in BALB/c (H2d ) mice (99). The tumor cell line used was TUBO
which was derived from a spontaneous mouse mammary tumor in BALB/c NeuT transgenic
mice (100). Treg depletion within 7 days of tumor inoculation led to increased anti-tumor
immune response and regression of tumors, as TUBO is sufficiently immunogenic to stimulate
the immune system. Protection was found to be long term in the Treg-depleted animals, as the
mice rejected a second tumor challenge even at week 14. Treg depletion also increased anti-mTg
immune response in animals injected with tumor followed by repeated injections of mTg (40 µg)
without LPS. This model had one drawback as it was not in an EAT-susceptible strain.
In another series of experiments, HER-2xDR3 and HER-2 transgenic mice were used to
study the regulation of tumor immunity and autoimmunity (101). These mice were generated to
simulate the clinical scenarios of HER-2 tolerant tumor patients with an HT-susceptible allele,
HLA-DR3 (101). The HER-2 tolerant mice harbored the human erB-2 gene (102) and HER-2
immunity was induced with HER-2 DNA vaccine in the presence of granulocyte monocytes
colony stimulating factor. It was found that anti-HER-2 immunity in HER-2 and HER-2xDR3
mice was increased after Treg depletion. While autoimmune responses against mTg were also
increased in HER-2 and HER-2xDR3 transgenic mice, anti-mTg T cell immune response was
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higher in DR3 transgenic mice, as expected. HER-2 immune responses were therefore
independent of HLA-DR3, whereas Tregs controlled the immune response to both antigens (mTg
and HER-2). This model is technically cumbersome, because HER-2 transgenic mice are
heterozygous and when mated with DR3 transgenic mice, the F1 animals would carry both DR3
and H2b genes.
In a third EAT-tumor model, BALB/c NeuT female mice which spontaneously develop
mammary tumors were used to examine the influence of tumor regression on mTg immunity
(103). There was significant enhancement of autoimmunity including thyroid pathology in mice
undergoing tumor regression. Thus, autoimmunity risk might be associated with increased
stimulus during vigorous anti-tumor immune responses.
These tumor-autoimmunity models provide us with a basic idea about the potential
problems which can be encountered in cancer patients suffering with tumors. These models,
though important in identifying the potential interplay between tumor immunity and
autoimmunity, focus more on the possible use of autoimmunity as an indicator for robust antitumor immune response, as well as potential undesirable side effects. They can also be used to
measure the increase in anti-tumor immune response due to autoimmunity in a synergistic or
additive manner. However, these models do not focus on autoimmune responses linked to
particular MHC molecules or the role of Tregs in controlling peripheral tolerance, since EATsusceptible strain may render stronger autoimmune responses. We therefore searched for a
combined model of tumor and autoimmunity in an EAT-susceptible strain.
V. EAT-tumor model in CBA/J (H2k) strain
Study in (DR3xH2b) F1 mice has shown that MHC class II haplotype has little or no
effect on tumor immunity but it has an effect on EAT induction (101). In EAT-susceptible strains,
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depletion of Tregs has been shown to enhance autoimmune responses and replenishing Tregs
reduces thyroid pathology (104). Similarly it has been shown that removing Tregs enhances the
anti-tumor immune responses in EAT-tumor models (99).
Searching for a suitable tumor in EAT-susceptible CBA/J mice led us to a tumor line
reported by Elliot et al. (105). This tumor arose spontaneously in a female retired CBA/J breeder.
The histology and the ultrastructural morphology were similar to mammary ductal carcinoma.
This cell line was designated as SP1 and was grown in vitro in cell cultures. After treatment with
DNA alkylating agents, a subline A22E-j was found to have a relatively high expression of MHC
class I (H2k) genes and is more immunogenic than the parent line. This cell line was cultured and
tested in vivo for both tumorigenic and immunogenic properties and was used as a stock tumor
line for our tumor-EAT model.
An initial report on the establishment of a anti-tumor induction model involves depleting
Tregs followed by vaccination with irradiated tumor cells 7 days apart (106). Subsequent
challenge with live tumor cells subcutaneously demonstrated 100% survival rate. For this
dissertation, the anti-tumor induction model has been combined with the EAT model where the
disease is induced by repeated injections of mTg (12).
As discussed previously, autoimmune thyroid disorders appear frequently during
immunotherapy protocols treating tumors or viral diseases. One of the reasons is the high
prevalence of a population with focal thyroiditis (3,107), existing as subclinical autoimmune
thyroiditis. As discussed previously, the study by McNeel et al. (85) demonstrated the potential
pitfalls of tumor immunotherapy administered with a systemic adjuvant which could enhance
pre-existing subclinical autoimmune hypothyroidism. Those patients with high antibody levels
against thyroglobulin had subclinical thyroiditis which was enhanced by the use a systemic
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adjuvant. We tried to create similar clinical scenarios in our mouse model of thyroiditis and
tumor.
Since in the clinical trials the end points are regression and patient survival, little effort
has been made forward understanding the genetics of the responses or potential side effects such
as severe autoimmune sequelae. To understand the basis of increased autoimmunity and assess
potential risk, we have attempted in our experimental designs to generate various clinical
scenarios in our mouse model and sought answers to some of the questions.
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CHAPTER 2

MATERIALS AND METHODS

Mice. CBA/J mice (females) were purchased at 6 weeks of age from Harlan Sprague-Dawley
(Frederick, MD, via C. Reeder, NIH). Mice were kept on acidified, chlorinated water before
being used at 8-12 weeks of age.
Preparation of peripheral blood leukocytes (PBL) for T cell subset analysis. The procedure
briefly involved collecting 0.5 ml of heparinized blood from each mouse from the tail artery. The
red blood cells were lysed with distilled water at room temperature, 4.5 ml/tube for 10 seconds,
after which the reaction was stopped by adding 0.5 ml of 10x phosphate buffered saline (PBS). It
was f ll wed by dd n 5

l f 1x H n s’ b l nced s lt s lut n nd w s n f

10

n by

centrifugation at 1000 rpm (120xg). The process was repeated twice.
mAbs and T cell subset depletion. For the depletion of Tregs in vivo, rat anti-mouse CD25
mAb was used. PC61 hybridoma cells (derived from parent cell lines: P3X63Ag8.653 (murine
myeloma cell line) and OFA rat spleen cells; ATCC, Manassas, VA) (108) were propagated in
the lab, frozen and sent to Harlan Bioproducts (Harlan Bioproducts for Science, Indianapolis, IN)
where hybridoma cells were injected into athymic nude mice and the resultant ascites fluid
served as the source of CD25 mAb (rat IgG1λ). PC61 concentration was determined with ELISA
anti-rat Igλ mAb (clone B46-5, mouse IgG1, BD Biosciences, San Jose, CA). CD4+CD25+ T
cells were depleted with two doses of 0.5 mg mAb iv 4 days apart prior to immunization as per
experimental protocol and the depletion was assessed by fluorescent activated cell sorter (FACS)
6 or 7 days after the second dose (104). While CD25 is a marker for Tregs, the most specific
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marker for Tregs is Foxp3 (41,109). In the EAT model, it has been shown previously that
CD4+CD25+Foxp3+ Tregs are responsible for peripheral tolerance, the removal of which
abrogates tolerance (25).
For FACS analysis, the PBL preparation was resuspended in FACS buffer (1% bovine
serum albumin, 5% normal rabbit serum, 0.1% sodium azide in 1x PBS) and labeled with
appropriate mAbs as described below.
For double labeling rat anti-mouse CD25 mAb conjugated with phycoerythrin (PE) (7D4,
rat IgM, Southern Biotech, Birmingham, AL), and rat anti-mouse CD4 mAb conjugated with
fluorescein isothiocyanate (FITC) (GK1.5, rat IgG2b, eBioscience, San Diego, CA) were used.
T e cells we e t en f xed nd e

e b l zed s e

nuf ctu e ’s nst uct ns

t l bel n

with Foxp3 mAb conjugated with cychrome 5.5 (FKJ-16S, rat IgG2a, eBioscience) to verify
depletion of CD4+CD25+Foxp3+ cells (usually 70-90% of the Tregs are depleted) (25).
For CD4 and CD8 T cell depletion, rat anti-mouse CD4 mAb (640 mg YTS191.1 + YTA
3.1, rat IgG2b) and rat anti-mouse CD8 mAb (320 mg YTS 169.4, rat IgG2b), kindly supplied by
Dr. H. Waldmann (Univ. Oxford, U.K.), were injected iv 4 days apart (110), after anti-tumor
vaccination at the times indicated in each protocol. Mice were bled 6-7 days after the second
dose of mAb to assess the depletion in PBL using FACS. In order to monitor the accurate
depletion of CD4+ and CD8+ T cells by FACS analysis, different antibodies were used for
labeling. For CD4+ T cells, mAb YTS 177.9.6 (rat IgG2a, kindly supplied by Dr. H. Waldmann)
against murine CD4 at 1:50 dilution was followed by biotinylated secondary mAb RG7/1.30
(murine IgG2b, BD Biosciences) against rat IgG2a at 1:100 dilution and Streptavidin-PE (BD
Biosciences) at 1:400 dilution. For CD8+ T cells, mAb YTS 105.18 (rat IgG2a, kindly supplied
by Dr. H. Waldmann) at 1:50 dilution was followed by biotinylated RG7/1.30 at 1:100 dilution
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and Streptavidin-PE at 1:400 dilution. Labeling with T cell receptor (TCR) mAb conjugated with
PE (H57-597, hamster IgG anti-mouse TCR) at 1:80 dilution, was performed to measure total T
cell number and assess depletion of different subsets of T cells.
Usually, 20,000 events/sample tube were acquired uncompensated on FACScan flow
cytometer (BD, San Jose, CA) and analyzed with FlowJo software (Tree Star, Inc., Ashland, OR)
(104).
Induction and assay of EAT.
Thyroglobulin. mTg was obtained from frozen mouse thyroids (Mayo Clinic, Rochester,
MN or Harlan Bioproducts for Science, or Pel-Freez LLC., Rogers, AR), fractionated on a
Sephadex G-200 column as previously described (22). Presence of LPS was checked in mTg by
the Limulus amebocyte assay (Associates of Cape Cod, Woods Hole, MA) (a 40 µg dose
contained <1ng of LPS). Aliquots were stored frozen at 2 mg/ml and diluted for use in
nonpyrogenic PBS.
Immunizations. EAT induction was carried out injection of 40 µg mTg in 0.1 ml iv
followed 3 hrs later by 20 µg LPS (trichloroacetic acid precipitated and kindly supplied by Dr. C.
Jeffries) in 0.1 ml on days 0, 7. Immunization or priming with mTg was also performed iv by
injection of 40 µg of mTg followed 3 hrs later with varying doses of IL-1, 5,000, 10,000 or
20,000U in 0.2 ml nonpyrogenic PBS, 7 days apart. IL-1 was purchased from eBioscience at 0.5
mg/ml which contained 1x104 units/µg. Immunization with mTg was also performed without
adjuvant by repeated injections of 20 or 40 µg mTg, 16 injections over 4 weeks (4 daily
injections/week at the first 4 days each week). In some experiments, CD4 +CD25+ T cells were
depleted with two doses of 0.5 mg CD25 mAb prior to immunization 4 days apart, to enhance
the responses to mTg (104).
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Proliferative response to mTg. Spleen cells (6x105 cells/well) were cultured in RPMI
plus 1% normal mouse serum (supplemented with 25 mM Hepes buffer, 100 U/ml penicillin, 100
µg/ml streptomycin, 2 mM L- lut

ne, 50 µM β-mercaptoethanol) for 5 days, at 37°C under 5%

CO2 with or without 40 μg/ml mTg in flat or round bottom 96-well tissue culture plates (Falcon,
USA). Cultured cells were pulsed with 1.0 µCi/well [3H] thymidine 18 hrs before harvesting
onto glass fiber filter paper (Tomtech Mach3Man Cell harvester, LKB Wallac, Gaithersburg,
MD). The incorporation of radioactive thymidine was assessed by a Microbeta Plus 1450 liquid
scintillation counter (LKB Wallac) (22).
Determination of mTg antibody. Mice were bled from the tail artery and the resulting
sera were stored at -20°C. mTg Abs were measured by ELISA, using plate-bound mTg (1
µg/well in Immunlon II microtiter plates) and alkaline phosphatase-labeled goat anti-mouse IgG
(Sigma), as described previously (38). The OD405nm values were corrected for nonspecific
binding by subtracting the OD of NMS.
Evaluation of thyroiditis. Histologic examination of H&E stained thyroids was used to
assess thyroid pathology. The thyroids with intact trachea were sectioned vertically through both
thyroid lobes (50-60 sections from 10-15 step levels). Mononuclear cell infiltration was scored
(double-blind) on an index of 0-4.0: 0, normal thyroid; 0.5 small interstitial foci of infiltration
involving >0-10% of the thyroid; 1.0, follicular destruction with >10-20% involvement; 2.0,>2040% involvement; 3.0, >40-80% involvement; and 4.0, >80% involvement (22).
Tumor model in EAT-susceptible CBA/J mice.
Tumor cell line, stock aliquots, and expansion for experimental use. A mouse
mammary adenocarcinoma cell line A22E-j was used in our lab (105). It was derived from the
tumor line, SP1, which originated as a spontaneous tumor in a retired female CBA/J breeder. The
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SP1 cell is virtually negative for expressing MHC class I molecules and is very tumorigenic but
not very immunogenic. Treatment of SP1 with 5-azacytidine (which inhibits DNA methylation
and is known to activate some genes) resulted in a less tumorigenic and more immunogenic A22
cell line with increased MHC class I expression (111). The histology and the ultrastructural
morphology were similar to mammary ductal carcinoma. A subclone of A22 tumor was resected
after growth in vivo and was designated A22E. Further subcloning resulted in the highly
immunogenic/MHC class I+ line, designated A22E-j (105,112). Both SP1 and A22E-j were
ndly su

l ed by D . B uce Ell t (Queen’s Un e s ty,

n st n, Ont

, C n da). When

immunogenicity and tumorigenicity of A22E-j cell line appeared stabilized as reported earlier
(106), the cell line was expanded twice and stored in aliquots in liquid nitrogen in supplemented
RPMI containing ~40% fetal calf serum (FCS, Atlanta Biologicals, Lawrenceville, GA) and 10%
dimethyl sulfoxide and used as stock for immunization, tumorigenesis and assay for tumor
antibodies.
For each experimental use, the stock A22E-j aliquots were thawed, washed, and cultured
in 75 cm2 tissue culture flasks in supplemented RPMI with 10% FCS as follows. When the
monolayer was 85-90% confluent, the cells were passaged. This involved removing the spent
medium, adding 5 ml of pre-warmed (37°C) RPMI, and incubating for 5 min in the CO2
incubator. After removal of medium, 5 ml of 0.125% trypsin was added, and the cells were again
incubated for 5 min at 37°C in the CO2 incubator, followed by washing twice at 1000 rpm
(120xg) for 5 min. The cultured tumor cells were expanded 2-3 times to achieve the required cell
numbers. No cells expanded for experimental use were returned to liquid nitrogen.
Induction of anti-tumor immunity with irradiated tumor cells. After in vitro
expansion, tumor cells were γ-

d ted (γ-tumor cells) with 10,000 rads using a cesium source
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(137Cs-Gammacell 40, Atomic Energy of Canada, Ltd., Ottawa, Canada). Untreated mice or mice
depleted of Tregs on days -14 and -10 with 0.5 mg CD25 mAb iv were immunized sc with 4x106
γ-tumor cells in the left inguinal region on days -7, 0 (106). For challenge, mice were inoculated
sc on day 0 with 1x105 live tumor cells in the right inguinal region. Tumor growth was
monitored 3x/week by palpation. Mice were sacrificed when any tumor dimension reached 20
mm or because of ulcerated tumor (106).
Tumor immunotherapy after tumor inoculation. Mice were first inoculated sc with
varying tumor doses of A22E-j on day 0 in the right inguinal region followed by Treg depletion
iv with CD25 mAb on days 0, 4. Mice were then immunized with 4x106 γ-tumor cells sc on days
7, 14 in the left inguinal region. Tumor growth was monitored 3 times/week and mice were
sacrificed when any tumor dimension reached 20 mm or because of ulceration.
Determination of tumor antibody. Sera were collected from mice with anti-tumor
immunized and unimmunized mice and stored at -20°C. A22E-j tumor cells were grown in 75
cm2 tissue culture flasks until 85-90% confluency. The cells were dislodged by first washing
with 1x RPMI at 37°C in incubator followed by 5 min at room temperature using 1x PBS-0.02M
ethylene diamine tetra-acetic acid (EDTA). The cells were then washed two times with complete
medium (10% FCS) and dispensed into 96-well plate (5x105/well). The cells were washed twice
in FACS buffer and resuspended. Serum samples at 1:10 or 1:20 dilution were then added to
each well (50 µl) for 30 min at 4°C and washed. AffiniPure F(ab)׳2 fragment from goat antimouse IgG conjugated to either FITC or PE (Jackson ImmunoResearch Laboratories, PA),
s ec f c f

Fcγ f

ent f
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30
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st e

controls, supernatant (50 µl/well) containing either anti-mouse H2Dk mAb (15-5-5S, murine
IgG2a) or anti-mouse H2Kk mAb (16-3-22S, murine IgG2a), both kindly supplied by Dr. B.
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Elliott, was used for MHC class I staining (80-90% of cells were positive, data not shown). A
positive antiserum from a previous experiment was also used as positive control. For negative
control, supernatant (50µl/well) containing anti-mouse IAd mAb (MK-D6, murine IgG2a, ATCC)
was used.
The labeled tumor cells were resuspended in FACS buffer processed through FACScan
flow cytometer; usually 20,000 events/sample tube were acquired uncompensated and analyzed
with FlowJo software. The antibody levels were shown as mean fluorescence intensity of FL1
(FITC) channel or FL2 (PE) channel. Early experiments with tumor antibody involved the use of
FITC-conjugated secondary antibody, background was subtracted using secondary antibody
alone. In order to improve sensitivity of the assay, brighter flurochrome, i.e. PE-conjugated
secondary antibody, was used and non-specific binding (with normal serum) was subtracted from
each serum sample before presenting the data.
Statistical analysis. Differences between groups of in vitro proliferation assays were analyzed
us n t e un

ed Student’s t-test. Histologic data and tumor antibody results were analyzed

non-parametrically with the Mann-Whitney U test. P values <0.05 were considered statistically
significant.
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CHAPTER 3
RESULTS

I. Characterization of anti-tumor immunity model in CBA/J mice.
As reviewed recently, there are various strategies to induce anti-tumor immune responses
(47). Inducing anti-tumor immune responses by various strategies however also leads to
activation of autoreactive T cells leading to autoimmune sequelae (107). The importance of the T
cell compartment in both autoimmunity and tumor immunity led us to design scenarios that
assess the contribution of CD4+ and CD8+ T cells and the known role of Tregs in regulating these
immune responses (25,99). In EAT, inhibiting Treg function leads to enhanced thyroiditis (25).
Treg depletion therefore serves as a good way of manipulating the immune system and
mimicking the impact of using immunotherapeutic or immunomodulatory regimens for treating
various disorders including cancers. Since the immunogenetics of various cancers were not well
known, we first examined combined autoimmunity and tumor models in EAT-resistant strains
(103). While Tregs are important in regulation of autoimmune, and anti-tumor immune responses,
only EAT has well-defined MHC class II-based susceptibility (12,20,113). For this reason, we
decided to design a combined autoimmunity and tumor model in our EAT-susceptible strain,
CBA/J mice.
A. Establishing tumor immunity induction protocol in CBA/J mice
Apart from maintaining peripheral self tolerance (40), Tregs masks the immune responses
to tumor antigens and depletion of Tregs unmasks the immune response leading to rejection of
established tumors (114,115). Treg depletion is important in the early phase of tumor immunity
which involves priming of immune cells against tumor antigens. Since we did not know what
tumor antigens in the A22E-j l ne
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cells as vaccines (106,116-118). We

un zed

ce us n γ-tumors cells with or without prior

depletion of Tregs and compared the immunity induced (Fig. 1A). The mice inoculated with
A22E-j tumor cells developed tumors starting on days 7-21. The groups treated with either Treg
de let n l ne

γ-tumor cells alone also showed a slightly delayed tumor growth but all

e entu lly succu bed. T e

ce

en T e de let n f ll wed by γ-tumor cells, the anti-tumor

induction protocol, showed 100% protection (Fig. 1B) against the growth of tumors. In order to
assess the role of antibodies in tumor protection, mice were bled at day 49, or earlier at the time
of sacrifice due to tumor growth. The highest antibody level was observed in the fully protected
group. Tumor-binding antibodies were analyzed by fluorescence intensity (Fig. 1C).
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Figure 1. Induction of anti-tumor immunity requires both Treg depletion and anti-tumor
immunization with irradiated tumor cells. A. Experimental protocol. On the days shown and
in groups of 8, mice were either depleted of Tregs with anti-CD25 mAb and immunized with tumor cells, depleted of Tregs alone, or immunized with -tumor cells alone. Treg depletion in
PBL was verified 7 days after the second dose of CD25 mAb by FACS analysis. On day 0, all
groups plus tumor control group were challenged with live tumor cells. Mice were bled and
sacrificed on day 49, or sooner, if one tumor dimension reached 20 mm or tumor became
ulcerated. B. Tumor growth was monitored 3x weekly and percent survival is shown. C. Tumorbinding antibody concentrations of individual mice at time of sacrifice were measured by
fluorescence intensity using the FITC-conjugated secondary antibody (see Materials and
Methods).
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B. Induced tumor immunity is protective against a second lethal challenge.
To examine the duration of induced tumor immunity, mice were depleted of Tregs and
un zed w t γ-tumor cells, followed by tumor challenge on day 0 (Fig. 2A). Mice were given
a second lethal challenge of 1x105 tumors on day 28 or day 35. Tumor control groups were
inoculated with tumors on day 0 and day 28 or 35. The animals were bled on day 28 and at the
time of sacrifice after the second lethal challenge. All mice in the tumor control groups
succumbed to the tumor. Mice with induced tumor immunity survived the first lethal dose, as
well as the second lethal dose given on day 28 or day 35 (Fig. 2B). Tumor antibody
concentrations were higher in mice with induced tumor immunity than tumor control groups and
remained unchanged after rechallenge (Fig. 2C).
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Figure 2. Induced tumor immunity is protective against a second lethal challenge at least 5
weeks later. A. Experimental protocol. On the days shown and in groups of 8, mice were
depleted of Tregs with anti-CD25 mAb and immunized with -tumor cells. Treg depletion in
PBL was verified 7 days after the second dose of CD25 mAb by FACS analysis. On day 0, all
groups plus tumor control group were challenged with live tumor cells. Two additional groups
were given a second challenge on day 28 or day 35. Mice were bled on day of sacrifice, or
sooner, if one tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth
was monitored 3x weekly and percent survival is shown. C. Tumor-binding antibody
concentrations were measured by fluorescence intensity using the PE-conjugated secondary
antibody. Sera were collected from mice after the first challenge (day 0) on day 28 and day 70.
Mice given a second lethal challenge on day 28 or day 35 were bled, respectively, 35 days or 28
days later.
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C. Role of CD4 and CD8 T cell subsets in tumor immunity
We examined the role of T cell subsets in protection against tumor challenge after antitumor induction. As s

wn n F . 3A, fte T e de let n f ll wed by tw d ses f γ-tumor

cells (the induction protocol for establishing anti-tumor immunity), CD4+ and/or CD8+ T cells
we e de leted w t

Abs

nst CD4
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immunization. The CD4+ and CD8+ T cell depletion was verified 6 days later (Fig. 3B). PBLs
were stained with CD4-FITC and CD8-FITC mAb to assess depletion. TCR-PE staining was
performed on all samples for comparison (data not shown). All mice given tumor alone
developed tumors, whereas immunization prevented tumor growth in the immunized control
group (Fig. 3C). The mice depleted of both CD4+ and CD8+ T cells did not develop any
protection against tumors and, in fact, succumbed at a rapid rate. In contrast, mice depleted of
CD4+ or CD8+ T cells alone were all protected from tumor growth. Comparing the tumorbinding antibody levels on day 56, the immunized group had higher antibody levels than the
CD4-depleted group, while the CD8-depleted group had tumor-binding antibody levels
comparable to the immunized control (Fig. 3D).
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Figure 3. Anti-tumor immunity is established by 14 days after Treg depletion and
immunization with irradiated tumor cells. A. Experimental protocol. Tumor immunity was
induced by Treg depletion and -tumor cell immunization in groups of 8 as shown. CD4+ and/or
CD8+ T cells were depleted with CD4 and/or CD8 mAbs 14 days after the second -tumor cell
dose (days -11, -7). Depletion in PBL was verified 6 days later (day -1) by FACS analysis. On
day 0, live tumor cells were injected. Mice were bled and sacrificed on day 56, or sooner, if one
tumor dimension reached 20 mm or tumor became ulcerated. B. Depletion of CD4 and CD8 T
cells was verified by FACS analysis of PBL with either CD4-FITC or CD8-FITC (2 mice/group).
C. Tumor growth was monitored 3x weekly and percent survival is shown. D. Tumor-binding
antibody concentrations were measured by fluorescence intensity using the PE-conjugated
secondary antibody.
See Next Page for Fig. 3B
30

31

B

31

32
Since tumor immunity was already established 14 days prior to T cell depletion, we
reduced the time interval for depletion of T cells. CD4+ and CD8+ T cells were depleted 7 days
fte t e sec nd d se f γ-tumor cells (Fig. 4A). In particular, we examined the role of tumor
antibodies in protective mechanisms. Mice were bled at three different time points: one, 7 days
fte f st γ-tumor cell dose (day -18), second, 6 days after depletion of CD4 and CD8 T cells
(day-1) and third, after the tumor inoculation (day 21) (Fig. 4B). Tumor-binding antibody
c ncent t ns 7 d ys fte t e f st γ-tumor dose were comparable in all the groups. Depletion
resulted in a drop in antibody concentrations 6 days later (day -1) in all groups, compared to the
immunized control. By day 21 after tumor challenge, however, antibody levels in all depleted
groups were increased and were comparable to the no-depletion controls (Fig. 4B). A
representative tumor-binding assay is depicted in Fig. 4C with the positive serum (1:20) in the
right panel.
As with the earlier experiment, all mice in the control group grew tumors, whereas all
mice in the immunized group were protected (Fig. 4D). Again, when both CD4+ and CD8+ T
cells were depleted, the animals succumbed at a more rapid rate than the controls. However, with
CD4+ T cell depletion alone, 3/8 mice did not survive. With CD8+ T cell depletion alone, one
mouse succumbed to the tumor challenge. Taken together there is requirement for CD4 and CD8
T cells; however they play a major role in anti-tumor protection.
Taken together, the data from both experiments suggests that protective mechanisms
require both CD4 and CD8 T cells to be fully established and continued after 14 days to prevent
tumor growth (Fig. 3). But CD4 T cells appeared to exert their influence beyond the 7-day
interval.
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Figure 4. CD4 and CD8 T cell subsets both play an important role in anti-tumor immunity.
A. Experimental protocol. Tumor immunity was induced by Treg depletion and -tumor cell
immunization in groups of 8 as shown. CD4+ and/or CD8+ T cells were depleted with CD4
and/or CD8 mAbs 7 days after the second -tumor cell dose (days -11,-7). Depletion of CD4+
and/or CD8+ T cells in PBL was verified 6 days later (day -1) by FACS analysis. On day 0, live
tumor cells were injected. Mice were bled on days -18, -1 and 21 and on day 49 at sacrifice, or
sooner, if one tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor-binding
antibody concentrations were measured by fluorescence intensity using the PE-conjugated
secondary antibody on three different time points prior to sacrifice: One, 7 days after the first tumor cell dose (day -18); second, 6 days after depletion of CD4+ and/or CD8+ T cells (day -1;)
and third, after tumor inoculation (day 21). C. Representative tumor antibody concentration is
depicted as overlays of histogram of PE channel. The binding of the non-specific serum sample
is shown in blue color with samples to be measured in black color (right panel, positive serum
62). D. Tumor growth was monitored 3x weekly and percent survival is shown.
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II. Examining concurrent induction of tumor immunity and its effect on autoimmunity in a
combined thyroiditis and tumor model.
A. Treg depletion and adjuvant-free model of EAT induction.
HT is an autoimmune disease which is modeled in mice using mTg as self antigen. The
adjuvant-free model of EAT induction has also been described where it was found that repeated
doses of soluble mTg could be used to induce moderate thyroiditis at about 50% incidence (12).
It was found further that Treg depletion before repeated injections increased the incidence and
enhanced severity (25). We repeated the experiment where Treg depletion was performed on
days -14, -10 prior to EAT induction by repeated administration of mTg for 4 weeks (Fig. 5A).
When we examined mTg antibody levels 35 days later at the time of sacrifice, the antibody
levels were much higher from the group with Treg depletion and repeated injections, compared
to the group with repeated mTg injections alone (Fig. 5B). Examination of thyroid pathology
from a composite of three experiments showed an increase of incidence in thyroid infiltration in
the group with prior Treg depletion compared to repeated mTg injections (54 vs. 36%) and
increased thyroid destruction (50 vs. 5%) (Fig. 5C).
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Figure 5. Treg depletion followed by repeated injections of mTg increases the incidence and
severity of thyroid pathology induced by repeated injections of mTg alone. A. Experimental
protocol. Mice were subjected to Treg depletion followed by repeated doses of mTg (40 µg, 16x),
or mTg injections alone on the days shown. Mice were bled and sacrificed 35 days after the first
mTg dose. B. mTg antibody levels were measured using ELISA (One representative experiment
of group of 8). C. Thyroids were harvested and percent thyroid infiltration from individual mice
is presented as composite of three experiments (n=22).
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B. Combined EAT and anti-tumor induction model.
In clinical scenarios, we envision tumor patients who are susceptible to autoimmune
thyroiditis being subjected to immunotherapy. The scenario could be a concurrent induction of
thyroiditis and tumor immunity as we have reported in EAT-resistant mice undergoing tumor
immunity induction after challenge (99,101,103). In EAT-susceptible CBA/J mice, we depleted
mice of Tregs followed by anti-tu

un z t n w t

γ-tumor cells. The mice were

inoculated with live tumor cells on day 0, followed by repeated administration of mTg from day
0-24 and sacrificed on day 35 (Fig. 6A). We assessed the influence of inducing EAT on tumor
incidence and percent survival. While control mice all succumbed to the tumor, anti-tumor
immunity provided 100% protection (Fig. 6B). No effect was observed on inhibition of tumor
growth by the presence of moderate EAT development (p=0.4). On the other hand, induction of
tumor immunity required Treg depletion (See Fig. 1), and thyroiditis was significantly enhanced
following repeated mTg doses to simulate physiologic release of circulatory mTg, compared to
mTg doses alone (p=0.01) (Fig. 6C).
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Figure 6. Induction of tumor immunity can exacerbate adjuvant-free EAT induction due to
prior Treg depletion. A. M ce, n
u s f 6, we e subjected t e t e T e de let n, γ-tumor
cell immunization, live tumor challenge on day 0, and repeated mTg injections as shown, or Treg
depletion and mTg injections only. They were bled and sacrificed on day 35 post-tumor
inoculation, or sooner, if one tumor dimension reached 20 mm or tumor became ulcerated. B.
Tumor growth was monitored 3x weekly and percent survival is shown. C. Thyroids were
harvested on day 35 post-tumor inoculation and percent thyroid infiltration is presented for
individual mice.
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III. Determining autoimmune sequelae based on the extent of autoimmunity prior to tumor
immunity enhancement regimen.
Of the various clinical scenarios envisaged, one scenario is tumor patients with ongoing
or subclinical autoimmune conditions being subjected to immunostimulation. One obvious
concern is the exacerbation of ongoing autoimmune responses. McNeel et al. (85) reported
elevated TSH levels and hypothyroidism in prostate cancer patients given peptide vaccine and
Flt-3 ligand as an adjuvant. Examined retrospectively, a high anti-thyroid antibody titer was
found in at least one patient who subsequently developed hypothyroidism, a clinical picture
consistent with pre-existing subclinical autoimmune hypothyroidism. We proceeded to mimic
the clinical scenarios in our model of thyroiditis and cancer.
A. Inducing EAT with various doses of mTg and IL-1
To mimic ongoing autoimmunity, we primed mice with 40 µg of mTg and various doses
of IL-1. IL-1 is one of the inflammatory cytokines released when LPS is used as T cell adjuvant
and high doses can substitute for LPS in EAT induction (24). We began by immunizing mice
with mTg and 20,000U IL-1, 7 days apart, on the days shown. Treg depletion and repeated doses
of mTg followed (Fig. 7A). At sacrifice, 35 days after the first mTg dose, splenocytes were
assayed for in vitro proliferative response to mTg. A strong response was observed from mice
immunized with mTg and 20,000U IL-1, which was not enhanced by additional Treg depletion
and mTg doses or mTg doses only (Fig. 7B). Mice with Treg depletion and repeated mTg
injections or repeated injections of mTg alone showed little mTg-specific proliferation. The
extent of thyroid infiltration of individual mice between the groups was compared (Fig. 7C).
Although mice given mTg and 20,000U IL-1 followed by Treg depletion and repeated mTg
injections had only marginally significant pathology over mTg and 20,000U of IL-1 only
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(p=0.06), these mice displayed significantly more severe thyroid destruction than mice with Treg
depletion and repeated mTg doses (p=0.007). These data suggest that, in EAT-susceptible mice,
pre-existing autoimmune condition could potentially be enhanced by the anti-tumor induction
regimen requiring Treg depletion.
We next titrated the IL-1 dose to reduce the degree of pre-priming toward subclinical
condition. Mice were given mTg and either 10,000U or 5,000U IL-1, followed by Treg depletion
and repeated injections of mTg (Fig. 8A). To ascertain that priming against mTg had occurred,
mice were bled 7 days after the second dose of mTg and 10,000U or 5,000U IL-1 and tested for
mTg antibodies. The mice showed measurable mTg antibody titers (Fig. 8B, day -15) which
increased at 11 days after the last dose of repeated mTg injections (Fig. 8B, day 35), with higher
levels in the 10,000U IL-1-treated group. Similarly, thyroiditis was more severe in the 10,000U
IL-1-treated than the 5,000U IL-1-treated group (Fig. 8C). There was no significant difference
between the group primed with mTg and 10,000U IL-1 and the group primed with Treg
depletion and repeated mTg injections and the group primed with mTg and 10,000U IL-1 alone
(p=0.4). There was also no significant difference between groups treated with mTg and the lower
dose of 5,000U IL-1, followed by Treg depletion and repeated mTg injections and the group
given anti-CD25 and repeated mTg injections only (p=0.3). However, in both 10,000U and
5,000U IL-1 pre-treated groups, thyroid pathology was significantly greater than mice without
pretreatment (p=0.002 and p=0.04 respectively). More importantly, 10,000U IL-1 alone
treatment induced significantly higher pathology than that of Treg depletion and repeated mTg
injections. However, thyroiditis induced with 5,000U IL-1 alone treatment was not different than
Treg depletion and repeated mTg injections. These data suggest that mTg + 5,000U IL-1 could
represent subclinical condition.
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Figure 7. Thyroiditis induced with mTg and 20,000U IL-1 is not affected by subsequent
Treg depletion and repeated mTg doses. A. Experimental protocol. Groups of 8 mice were
either immunized with 40 µg mTg and 20,000U IL-1, followed by Treg depletion and/or
additional doses of mTg on the days shown. Mice were bled and sacrificed 35 days after the first
mTg dose. B. In vitro proliferative response to mTg was assessed by [3H] thymidine uptake of
cultured spleen cells and shown with background CPM (see Materials and Methods).C. Thyroids
were harvested and percent thyroid infiltration is shown for individual mice.
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Figure 8. Thyroiditis induced with mTg and either 5,000U or 10,000U represents mild to
moderate pre-existing autoimmunity which is not exacerbated by subsequent Treg
depletion and repeated mTg doses. A. Experimental protocol. Mice, in groups of 6-8, were
either primed with 40 µg mTg and either 10,000U or 5,000U IL-1 followed by Treg depletion
and/or additional doses of mTg on the days shown. Mice were bled and sacrificed 35 days after
the first repeated injection mTg dose. B. Mice were bled on days -15, 35 for serum and mTg
antibody levels were measured by ELISA. The bars represents mean of the antibody level of all
mice in the group (n=6). C. Thyroids were harvested and percent thyroid infiltration is presented
for individual mice (n=6).
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B. Combining pre-priming to mTg and 10,000U IL-1 with tumor immunity induction.
We first tested pre-priming with mTg and 10,000U IL-1, followed by induction of tumor
immunity with T e de let n nd γ-tumor cell immunization (Fig. 9A). Whereas, control mice
given live tumor cells succumbed to the tumor, induced tumor immunity protected 100% of the
mice as before (Fig. 9B). All mice in the group pre-primed with mTg and 10,000U IL-1 also
survived. To determine if tumor challenge would affect the extent of thyroid infiltration, mice
primed with mTg and10,000U IL-1 alone were killed 28 days after priming and compared with
those sacrificed 35 days after tumor inoculation (day 63 after priming). Both groups developed
mild to moderate thyroiditis, which was not affected by subsequent tumor inhibition (Fig. 9C).
To assess the role of physiologic release of mTg, we administered additional mTg doses.
Mice were pre-

ed, de leted f T e s nd

en γ-tumor cells and live tumor challenge,

followed by repeated mTg injections (Fig. 10A). The percent survival remained 100% and not
affected by repeated mTg injections (Fig. 10B). Tumor-binding antibody concentrations
determined at sacrifice on day 35 were similarly high in mice with induced tumor immunity and
in mice pre-primed with mTg and 10,000U IL-1 and repeated mTg injections (Fig. 10C). On day
35, the extent of thyroid infiltration was also unchanged by the presence of tumor growth
inhibition or additional mTg injections (Fig. 10D).
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Figure 9. Induced anti-tumor immunity has no effect on ongoing EAT induced with mTg
and 10,000U IL-1 and vice-versa. A. Experimental protocol. Groups of 8 mice were either
unimmunized or immunized with 40 µg mTg and 10,000U IL-1, followed by induction of tumor
immunity and lethal tumor challenge. Some mice were sacrificed on day -1 prior to tumor
challenge on day 0 to assess thyroiditis; otherwise, mice were sacrificed on day 35, or sooner, if
one tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth was
monitored 3x weekly and percent survival is shown. C. Thyroid pathology obtained on day 35 is
presented as percent thyroid infiltration for individual mice (n=8).
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Figure 10. Additional doses of mTg coupled with induction of anti-tumor immunity does
not affect ongoing EAT induced with mTg and 10,000U IL-1 and vice-versa. A.
Experimental protocol. Mice, in groups of 6-8, were either unimmunized or immunized with
mTg and 10,000U IL-1 followed by induction of anti-tumor immunity and lethal tumor challenge
on day 0. On days 0-24, repeated mTg doses were also administered to one group. For tumor
antibody assay, mice were bled and sacrificed on day 35 post-tumor inoculation, or sooner, if one
tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth was monitored
3x weekly and percent survival is shown. C. Tumor-binding antibody concentrations were
measured by fluorescence intensity using the FITC-conjugated secondary antibody (n=6-8). D.
Thyroids were harvested on day 35 and percent thyroid infiltration is presented for individual
mice (n=6-8).
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C. Mild thyroiditis induced with mTg and 5,000U IL-1 is enhanced when combined with
tumor immunity induction and repeated mTg doses.
The above experiment was repeated with the lower 5,000U IL-1 dose to represent a mild
subclinical condition (Fig. 11A). Again, the percent survival remained 100% in the presence of
ongoing EAT (Fig. 11B). Thyroiditis in the group primed with mTg and 5,000U IL-1 along with
Treg depletion and repeated mTg doses was significantly higher than the thyroiditis in the group
treated only with Treg depletion and mTg injections (p=0.01) (Fig. 11C). Thyroiditis induced
with mTg and 5,000U IL-1 with Treg depletion and repeated mTg doses was also significantly
higher than thyroiditis in mice primed with mTg and 5,000U IL-1 only (p=0.04). Tumor growth
inhibition in mice with induced tumor immunity did not further affect nor increase the
autoimmune response (p=0.2). Thus, although induced tumor immunity was not compromised,
thyroiditis severity could be exacerbated by the tumor immunity induction regimen involving
Treg depletion and the simulation of physiologic release of mTg.
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Figure 11. Mild thyroiditis induced with mTg and 5,000U IL-1 is enhanced when combined
with induction of anti-tumor immunity and additional doses of mTg without affecting
tumor immunity. A. Experimental protocol. Mice, in groups of 6-8, were primed with 40 µg
mTg and 5,000U IL-1, followed with or without anti-tumor induction and tumor challenge (day 0)
and additional doses of mTg (days 0-24) as shown. They were sacrificed on day 35, or sooner, if
one tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth was
monitored 3x weekly and percent survival is shown. C. Thyroids were harvested and percent
thyroid infiltration is presented for individual mice (n=6-8).
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IV. Establishing an immunotherapeutic protocol to combat tumor growth in CBA/J mice.
Our tumor immunity induction protocol is a prophylactic model to inhibit tumor growth.
Tumor regression can release various pro-inflammatory cytokines which could enhance the
ongoing autoimmunity as was seen in the EAT-resistant strain (103). Since our tumor model was
in an EAT-susceptible strain and the A22E-j tumor was fast-growing and lethal, it was of
particular interest to determine: 1) If an immunotherapeutic model to suppress tumor
development was feasible; and 2) if pre-existing autoimmunity could be influenced by the
induced tumor inhibition.
A. Setting up the model to inhibit tumor growth.
We began with the lethal A22E-j tumor dose studied above and inoculated mice with
1x105 or half the dose of 5x104 on day 0. On the same day, we initiated the tumor immunity
induction regimen. The mice were depleted of Tregs on days 0, 4 nd

un zed w t γ-tumor

cells on days 7,14 (the immunotherapy protocol) (Fig. 12A). Tumor growth was presented as
tumor volume from individual mice. The immunotherapy group with Treg depletion and γ-tumor
cell immunization did not protect mice from tumor growth with 1x105 tumor dose, nor did Treg
depletion

γ-tumor cells alone (Fig. 12B). We calculated the percent survival from the mice

with 1x105 tumor dose from a composite of two identical experiments, which reiterated that
immunotherapy regimen was not effective for 1x105 tumor dose (Fig. 12C). Tumor antibody
concentrations were evaluated on day 42 and showed that, despite high antibody levels in the
Treg-depleted and immunized group (Fig. 12D), death was only delayed in 70% of the mice
which eventually succumbed (Fig. 12C).
When the tumor dose was reduced by half to 5x104 (Fig. 12A), 3 of 6 animals were
tumor-free with T e de let n nd γ-tumor cell treatment (Fig. 12E). In a repeat experiment, 4
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of 6 mice were tumor-free. Anti-CD25

γ-tumor cells alone did not protect the mice against

5x104 tumor dose in either experiment (Fig. 12E). Percent survival from a composite of these
two experiments showed 58% protected of the mice in the Treg depletion and γ-tumor cell
treatment group (Fig. 12F). Comparing the tumor antibody levels, the immunotherapy group had
significantly higher antibody levels than the other groups (Fig. 12G), but clearly the tumor
antibodies were not sufficient to suppress tumor growth.
We next repeated the use of 5x104 tumor dose and compared it with a dose reduced by
half to 2.5x104 tumor dose. With the 5x104 tumor dose, we again observed 50% (4/8) of the mice
tected

nst tu

wt by T e de let n nd γ-tumor cell treatment (Fig. 13B). One of

the four protected mice had an early palpable tumor which then regressed. In a repeat experiment,
5 of 8 mice were tumor-free. Percent survival from a composite of these two experiments
showed 44% survival with 5x104 tumor dose (Fig. 13C).
With the 2.5x104 tumor dose, none of the 8 mice treated with the immunotherapy regimen
developed progressive tumors; 2 of the 8 developed palpable tumors which then regressed. The
tumor control group showed a more retarded tumor growth, but all eventually succumbed,
indicating that 2.5x104 cell dose is nevertheless lethal. In a repeat experiment, all 8/8 mice in the
immunotherapy group again inhibited tumor development. Percent survival from these two
experiments, showing the successful immunotherapeutic regimen, is presented in Fig. 13E.
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Figure 12. Induction of anti-tumor immunity at the same time as tumor inoculation affords
no protection at 1x105 tumor dose, but partial protection at 5x104 tumor dose. A.
Experimental protocol. In groups of 6, mice were inoculated with either 1x105 or 5x104 tumor
cells on day 0. Mice were depleted of Tregs with CD25 mAb and immunized with -tumor cells,
depleted of Tregs alone, or immunized with -tumor cells alone as shown. Mice were bled and
sacrificed on day 56, or sooner, if one tumor dimension reached 20 mm or tumor became
ulcerated.
For 1x105 tumor dose:
B. Kinetics of tumor growth is shown as tumor volume for individual mice from one
experiment. C. Tumor growth was monitored 3x weekly and percent survival is shown from a
composite of two experiments. D. Sera were collected at day 42 post-tumor inoculation and
tumor-binding antibody concentrations were measured by fluorescence intensity using the FITCconjugated second antibody from a composite of two experiments.
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For 5x104 tumor dose:
E. Kinetics of tumor growth is shown as tumor volume for individual mice from one experiment.
F. Tumor growth was monitored 3x weekly and percent survival is shown from a composite of
two experiments. G. Sera were collected at day 42 and tumor-binding antibody concentrations
were measured by fluorescence intensity using the FITC-conjugated secondary antibody from a
composite of two experiments.
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Figure 13. Induction of anti-tumor immunity at the same time as a lower but lethal tumor
dose of 2.5 x104 results in 100% protection. A. Experimental protocol. Mice, in groups of 8,
were inoculated with either 5x104 or 2.5x104 tumor cells on day 0, and depleted of Tregs with
CD25 mAb and immunized with -tumor cells as shown. Mice were bled and sacrificed on day
42, or sooner, if one tumor dimension reached 20 mm or tumor became ulcerated. B & C for
5x104 tumor dose, D & E for 2.5x104 tumor dose: B, D, Kinetics of tumor growth is shown as
tumor volume for individual mice from one experiment. C, E. Tumor growth was monitored 3x
weekly and percent survival is shown from a composite of two experiments.
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B. Protective mechanisms in the immunotherapeutic model.
We next examined the role of CD4 and CD8 T cell subsets, as well as tumor-binding
antibodies, in this immunotherapeutic model using the 2.5x104 tumor cell dose. CD4 and/or CD8
T cells were depleted as before with two doses 4 days apart (days 17, 21), at 3 days after the
sec nd γ-tumor cell dose. Mice were bled on day 16 just prior to depletion and at sacrifice on
day 42. Whereas the immunotherapy protocol initiated at the time of tumor inoculation again
inhibited tumor development in 100% (16/16) of the mice, depletion of both CD4 and CD8 T
cells resulted in only 20% (3/16) survival (Fig. 14B). Tumor-binding antibody levels showed
little change from day 16 to day 42 in the no depletion group (Fig. 14C). In the CD4-depleted
group, there was a reduction in antibody levels at day 42, and in the CD8-depleted group,
antibody levels were somewhat higher. Since the antibody levels in the CD4- and CD8-depleted
mice showed similar levels to the non-depleted group, these antibodies appeared to play a minor,
if any, role in inhibiting tumor growth.
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Figure 14. CD4 and CD8 T cell subsets both play an important role in tumor immunity
induced along with tumor inoculation. A. Experimental protocol. Mice, in groups of 8, were
inoculated with 2.5x104 tu
d se, f ll wed by T e de let n nd γ-tumor cell immunization.
Anti-CD4 and/or anti-CD8 depletion was carried out with two doses of mAbs, 4 days apart (days
17, 21), t 3 d ys fte t e sec nd γ-tumor cell dose, as shown. Depletion was verified 7 days
later by FACS analysis. Mice were bled on day 16 and at sacrifice on day 42, or sooner, if one
tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth was monitored
3x weekly and percent survival is shown from a composite of two experiments. C. Tumorbinding antibody concentrations were measured by fluorescence intensity using the PEconjugated secondary antibody. Data from day 16, prior to CD4 and CD8 T cell depletion, and
day 42 from one experiment are presented (n=8).
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C. Determining mutual effect of subclinical EAT and tumor immunotherapy regimen.
Mice were primed with mTg and 5,000U IL-1, followed by live tumor inoculation at the
time of initiation of tumor immunity induction. First, we tested with 5x104 tumor dose (Fig. 15A).
As shown previously in Fig. 12F and Fig. 13C, about 50-60% survival could be obtained by the
immunotherapy regimen (Fig. 15B). Thus, little effect was observed due to pre-priming with
mTg and 5,000U IL-1 and additional mTg doses. As before, thyroiditis induced with mTg and
5,000U IL-1 pre-priming and additional Treg depletion and mTg injections was significantly
higher than that observed with Treg depletion and repeated injections of mTg (p=0.02) (Fig.
15C). On the other hand, thyroiditis induced with mTg and 5,000U IL-1 alone was not
significantly different from the group with added Treg depletion and repeated mTg injections
(p=0.3). Ongoing immunotherapy and tumor growth inhibition had no observable influence on
EAT induction (Fig. 15C).
As previously observed (Fig. 13E), the tumor immunotherapy protocol afforded 100%
protection to the 2.5x104 tumor dose. When combined with pre-priming (mTg and 5,000U IL-1)
and added Treg depletion and mTg doses (Fig. 16A), no discernible influence was seen by the
ongoing thyroiditis on tumor immune responses, which remained at 90% survival (Fig 16B). In
the reverse, thyroiditis induced with mTg and 5,000U IL-1 with added immunotherapy regimen
and repeated mTg injections was not significantly different from the group without the
immunotherapy regimen (Fig 16C).
In conclusion, both the tumor doses when combined with mTg and 5,000U of IL-1 prepriming did not have any adverse effect on the ongoing thyroiditis and vice-versa.
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Figure 15. Partial protection afforded by induction of tumor immunity to 5x104 tumor
inoculation is unaltered by ongoing EAT and additional mTg doses. A. Experimental
protocol. Mice were primed with 40 µg mTg and 5,000U IL-1 only, or primed and given antiCD25 nd γ-tumor cell doses along with 2.5x104 tumor dose, followed by repeated mTg doses as
shown. Control mice received anti-CD25 and repeated mTg doses following priming. B. Mice
from tumor-injected groups were sacrificed on day 55, or sooner, if one tumor dimension
reached 20 mm or tumor became ulcerated. Tumor growth was monitored 3x weekly and percent
survival is shown. C. Thyroids were obtained 41 days after the first mTg doses and percent
thyroid infiltration is presented for individual mice (n=6-8).
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Figure 16. Protection afforded by induction of tumor immunity to 2.5x104 tumor
inoculation is unaltered by ongoing EAT and additional mTg doses. A. Experimental
protocol. Mice were primed with 40 µg mTg and 5,000U IL-1 only, or primed and given
anti-CD25 nd γ-tumor cell doses along with 2.5x104 tumor dose, followed by repeated
mTg doses as shown. Control mice received anti-CD25 and repeated mTg doses
following priming. Mice from tumor control group were sacrificed on day 49, or sooner,
if one tumor dimension reached 20 mm or tumor became ulcerated. B. Tumor growth was
monitored 3x weekly and percent survival is shown. C. Thyroids were harvested at day
49, 11 days after the repeated mTg doses and percent thyroid infiltration is presented for
individual mice from one experiment (n=6-8).
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CHAPTER 4
DISCUSSION
I. Characterization of anti-tumor immunity model in CBA/J mice
Our attempt to develop an anti-tumor induction model in EAT susceptible CBA/J mice
was to simulate the clinical scenarios of patients with susceptible alleles being subjected to
immunotherapy. Central tolerance mechanisms take care of many autoreactive T cells but there
is always a pool of autoreactive T cells in the periphery which can be primed to react to selfantigens. These autoreactive T cells are kept in check by the Tregs, either natural or induced,
breaking tolerance is the way forward to make immune system respond robustly against the
tumor which sometimes leads to sequelae such as increased autoimmunity or enhancement of
ongoing autoimmune responses (69).
We developed our anti-tumor induction model using Treg depletion prior to anti-tumor
un z t n w t γ-tumor cells (Fig. 1A) and found that combined Treg depletion and antitumor immunization treatment was required for protection against lethal tumor challenge. This
was also observed previously in an EAT-resistant strain, where Treg depletion coupled with
DNA vaccine led to tumor rejection (103). Treg depletion can overcome the dominant tolerance
mechanism exerted by Tregs on self-antigens, but has to be coupled with immunization to prime
and activate autoreactive T cell pool. Along with the immunization, Treg elimination creates a
beneficial host microenvironment by affecting host innate immune system (119).
The anti-tumor immunization that we employed was using irradiated whole tumor cells.
Whole cell vaccines are attractive when the tumor antigens are not defined, tumor antigens on
surface could be presented to T cells through the MHC class I and class II pathway, avoiding the
problem of finding MHC restricted epitope (118,120). Vaccination with whole tumor cell
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vaccines induce immune response, priming CD8+ and CD4+ T cells via cross-presentation or
direct tumor-antigen presentation respectively, and by prolonged release of tumor associated
antigens taken up by APCs for the activation of immune effector cells (121).
We also sought to understand the long term protection involved in anti-tumor induction
model. It was found that mice withstood secondary tumor inoculation 4-5 weeks after the
primary challenge demonstrating long-term memory response in our model. Our results are
similar to previous models of autoimmunity and EAT where long-term protection was observed
in mice in BALB/c mice and NeuT transgenic mice (99,103) where antibody and T cell
responses were still detectable at week 60 after primary immunization (103). In our model, even
though we do not have an assay to measure the T cell responses, experimental evidence suggests
that T cells are playing a major role in anti-tumor immune responses (Fig. 3B and Fig. 4D) and
maybe in the long term memory responses as well. The antibody levels were not elevated after
secondary tumor inoculation, but this assay is inadequate to define its role in tumor protection.
We also attempted to define the protective mechanism involved and found involvement
of CD4+ and CD8+ T cells. The immunity is T cell-mediated as evidenced by depletion of both
CD4+ and CD8+ T cells leading to complete lack of development of protection. With the 14 days
time interval between immunization and depletion of T cells, complete loss of protection was
observed with combined CD4+ and CD8+ T cells depletion. However, there was no loss of
protection observed with either CD4+ or CD8+ T cell depletion alone indicating that tumor
protection was already well established by the time of depletion and taking out single component
did not perturb the immune response. Since the importance of each T cell subset could not be
discerned with the protocol, we performed the experiment with a shorter time period between
immunization and depletion of T cells, i.e. a 7-day time interval. As with previous experiment,
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depletion of both CD4+ and CD8+ T cells led to complete lack of development of protection. We
can also surmise that both CD4+ and CD8+ T cells have a synergistic role in tumor protection.
Similarly, tumor antibody levels were found to be elevated comparably in all groups at day 21,
28 days after depletion especially in the combined CD4 and CD8 group where there was
complete lack of protection against tumor growth. This suggests that antibody has very little role
to play in the protection. However, in the absence of any functional assay to further define its
role, we speculate that antibody has a secondary role in the protective mechanism and the major
role is T cell-mediated.
II. Examining concurrent induction of tumor immunity and its effect on autoimmunity in a
combined thyroiditis and tumor model.
EAT is an induced disease model where one needs to break tolerance in order to prime
autoreactive T cells against mTg. Breakdown of tolerance could be accomplished by the use of
adjuvants or even by repeated administration of antigen alone without adjuvant. Adjuvant-free
model of EAT induction leads to a weaker thyroiditis characterized by infiltration of thyroid in
50% of the mice and some destruction of thyroid follicles (Fig 5C) (12). But when the same
protocol is repeated with prior depletion of Tregs which lowers the threshold for the mTgspecific autoreactive T cells to be primed and activated, there is increased incidence and severity
of thyroiditis in susceptible strain (25). This shows that genetic component (MHC class II) and
Tregs complement each other in defining susceptibility to autoimmune disorder. Since in the
earlier section, we also learned that Treg depletion and anti-tumor immunization both are
necessary and sufficient to induce a robust anti-tumor immune response, we combined the two
protocols in order to observe any enhancements of immune responses either way and to simulate
clinical scenarios of tumor patients undergoing immunotherapy (Fig. 6A). Adjuvant-free model
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of EAT induction was used to evaluate less pronounced changes in susceptibility and also to
simulate physiologic release of mTg in the host. Use of adjuvant was also avoided to prevent
undue beneficial effect to the tumor immune responses. There was no adverse effect of tumor
immunotherapy on EAT and vice-versa. Prior depletion of Tregs however enhanced thyroiditis
induced with repeated injections of mTg emphasizing the importance of Tregs in maintaining
peripheral tolerance in EAT model, and also in the anti-tumor induction model where prior Treg
depletion helps in inducing anti-tumor immune response to reject tumor growth (Fig. 6B).
Therefore, the results suggest that anti-tumor induction protocol is detrimental to autoimmune
thyroiditis in our mouse model. However, examining the components involved, Treg depletion
(tumor immunomodulation) nd n t γ-tumor cell treatment is responsible for the enhancement
observed in EAT. This is in line with the clinical picture where tumor immunomodulation
enhances autoimmunity; tumor vaccination regimen however may or may not influence
autoimmunity. In our mouse model, both EAT and anti-tumor immune responses were not
influenced by each other. However, in an combined model of EAT and tumor in BALB/c mice,
we found synergistic enhancement of immune response against tumor (HER-2) and to mTg
during tumor regression when there was a concurrent induction of tumor immunity and EAT (99).
Similar mutual amplification was also observed in (HER-2xDR3) F1 transgenic mouse model of
tumor immunity and EAT (101). It was hypothesized that it being a model of tumor regression,
regressing tumor led to the release of inflammatory cytokines systemically, which not only
enhanced thyroiditis but also anti-tumor immune responses. In our tumor induction model, there
is no tumor regression, instead we are preventing the growth of the tumor. In clinical scenarios
however, patients are subjected to systemic immunomodulators and other treatment modalities
such as irradiation which can further enhance both anti-tumor and autoimmune responses.
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III. Determining the autoimmune sequelae based on the extent of autoimmunity prior to
tumor immunity enhancement regimen.
As we discussed previously, immunotherapy often brings up autoimmune sequelae or
exacerbate ongoing autoimmunity in patients in clinical trials. In order to mimic it, we set up
tumor immunotherapy model with ongoing thyroiditis to look for exacerbation.
We started with various doses of IL-1 to prime mice against mTg. IL-1 has been used
here as a T cell adjuvant (24). Addition of exogenous IL-1 has been shown to act as adjuvant
when administered alongside antigen in different animal models of autoimmunity (24,122).
Apart from the adjuvant properties, IL-1 has been shown to break tolerance against self antigens
by priming and expanding effector T cells (24,123) and by inhibition of CD4+CD25+ Tregs (122).
IL-1 has a pleiotropic effect on many immune cells leading to proinflammatory environment
locally and systemically, which promote autoimmune conditions. Since IL-1 was a weaker
stimulus than LPS itself, we used it to prime mice against mTg to observe subtle changes of
susceptibility and used it to define pre-existing or ongoing autoimmune condition to be further
subjected to anti-tumor induction protocol.
Our priming experiments started by using 20,000U IL-1, which was the highest dose
tested. mTg and 20,000U IL-1 treatment for priming induced thyroiditis in all mice (Fig 7C),
which was found to be severe than that of Treg depletion and repeated mTg injections. Addition
of Treg depletion and mTg repeated injections however did enhance the ongoing thyroiditis
marginally. This gave us the first indication that ongoing autoimmunity could be enhanced
further. Examining the results further, we decided to test lower doses of IL-1 in order to define
various gradations of ongoing autoimmunity. We compared pre-priming of 10,000U with that of
5,000U IL-1. mTg and 10,000U IL-1 induced thyroiditis in all mice in the group (Fig 8C).
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Addition of Treg depletion and repeated mTg injections (20 µg) however did not significantly
enhance ongoing thyroiditis. Similar results were also evident with mTg and 5,000U IL-1 prepriming. However, the 5,000U IL-1 dose was found to be weaker compared to 10,000U IL-1
dose and was classified as being subclinical.
As we observed previously with tumor experiments, combined T e de let n nd γtumor cell treatment form anti-tumor induction model (Fig. 1-4). We have also observed that
with various doses of IL-1 (20,000, 10,000 or 5,000) used for priming along with mTg, there was
an indication of enhancement with addition of Treg depletion and repeated mTg injections. In
order to assess the effect of tumor and anti-tumor induction protocol on ongoing thyroiditis, we
combined the mTg and 10,000U IL-1 pre-priming with tumor immunity induction to mimic the
clinical scenarios and also to observe the influence of autoimmunity and tumor protection viceversa. The results indicated lack of any deleterious effect of tumor immunity on ongoing
thyroiditis and vice-versa. We further added repeated mTg injections to mimic physiologic
release of mTg in the host, however, no enhancement was observed with additional stimulation.
mTg and 10,000U IL-1 pre-priming is therefore enough to break tolerance to mTg and induce a
stronger thyroiditis compared to that induced with repeated mTg injections. Adding weaker
restimulation to the ongoing autoimmunity did not enhance the thyroiditis further. Our tumor
immunity induction is very strong and induces 100% protection all the time. As evident in our
earlier results (Fig 3B and Fig 4B), the tumor immune responses are established early and last for
the duration of the experiment. That is one of the reasons that we did not observe any influence
of ongoing EAT on induced tumor protection. This result of ours may or may not be a true
picture of clinical scenarios. In clinics, patients are subjected to many different regimens at the
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same time and the perturbation of the immune system in one host might influence the ongoing or
induced immune responses.
The pre-priming dose of 5,000U IL-1 induced mild thyroiditis in mice but inconsistently
in the group. We wanted to explore this further and, as with 10,000U IL-1, combined the priming
dose of 5,000U IL-1 with tumor immunity induction and added soluble mTg doses to simulate
physiologic release of mTg. In our model of combined EAT and tumor protection, the anti-tumor
immune responses and autoimmune thyroiditis were unchanged in the presence of each other or,
there might be some influence which we were not able to observe because of the shortfall of the
model. Ongoing thyroiditis induced with mTg and 5,000U IL-1 combined with Treg depletion
and repeated mTg injections was significantly enhanced when combined with additional Treg
depletion and repeated mTg injections. We can surmise from the results that individual
components such as Treg depletion and repeated mTg injections when combined together can
certainly exacerbate ongoing thyroiditis in certain conditions. This suggests that the priming dose
of 10,000U IL-1 is too strong and therefore is enough to make all autoreactive T cells cross the
threshold needed to be activated, a weaker stimulus such as additional mTg doses therefore was
unnecessary as the pool of autoreactive T cells were already activated. In contrast, with 5,000U
IL-1, the priming dose is not enough to make all autoreactive T cells cross the threshold to be
activated. Additional stimulation with Treg depletion and repeated mTg injections helps the
unprimed autoreactive T cells reach the threshold for priming leading to exacerbated thyroiditis.
This could be one of the reasons why we observe such a wide range of fluctuations with 5,000U
IL-1 dose. Similarly, our EAT induction protocol with repeated mTg injections is also variable in
priming autoreactive T cells and induces weak thyroiditis in about 50% of mice in our
susceptible strain. Adding Treg depletion lowers the threshold for activation of autoreactive T
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cells and inducing thyroiditis. However, significant enhancement with the protocol was observed
less frequently and is also one of the reasons for variability on the final exacerbation of
thyroiditis. Combining everything together for interpretation makes it clear why some patients,
and not all patients, undergoing immunotherapy could present autoimmune sequelae. Our work
has demonstrated the importance of pre-existing subclinical condition which can be enhanced
under favorable conditions to present clinical autoimmune disease.
In a melanoma brain tumor model, shared melanoma antigen also expressed by skin and
brain tissue was used to prime the immune system (124). The tumor growth in brain was rejected
by vaccination but did not lead to any autoimmune responses in the brain inspite of shared
antigen. However, the autoimmune responses were observed in skin only when an inflammatory
response was induced prior to anti-tumor vaccination. This is similar to our results with ongoing
inflammation, only subclinical autoimmune condition was shown to be enhanced in our mouse
model.
IV. Establishing an immunotherapeutic protocol to combat tumor growth in CBA/J mice.
As discussed previously in the concurrent model of EAT and anti-tumor induction, tumor
regression influenced the outcome of thyroiditis in combined EAT and tumor model, in neu
transgenic BALB NeuT female mice (103) with significant EAT enhancement observed only in
mice undergoing tumor regression after HER-2 DNA vaccination (103). Since we observed this
phenomenon in an EAT-resistant strain, we wanted to further explore the implications of tumorgrowth prevention after tumor inoculation (therapeutic as opposed to prophylactic in earlier
experiments) in an EAT-susceptible strain. For this reason, we set up immunotherapy regimen in
CBA/J mice. We tested different doses of tumor cells for protection and first tested two doses,
1x105 and 5x104 tumor cells. With 1x105 dose, no protection was observed with immunotherapy
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protocol (Fig 12C). This lethal dose is fast growing with palpable tumors as early as day 7 posttumor inoculation (Fig. 12B). In previous experiments, our aim was to prevent the growth of the
tumor after induction of anti-tumor immune responses. We also assessed from our T cell subset
depletion studies that anti-tumor immune responses are induced as early as 7 days post-tumor
inoculation. Inspite of starting the immunotherapy regimen as early as day 0 with Treg depletion
nd γ-tumor cell treatment by day 7, we were not able to prevent the growth of the tumor. Treg
de let n n

γ-tumor cell treatment alone helped in slowing down or protect mice from the

tumor growth. With 5x104 tumor cells, 50% protection was achieved with immunotherapy
protocol (Fig. 12F). This tumor dose, although lethal, did not grow as fast the previous dose.
Mice started showing palpable tumors on day 14 post-tumor inoculation, although there was
variability in terms of tumor growth (Fig. 12E). Our immunotherapy regimen therefore was able
to inhibit tumor growth in at least 50% of mice in the group. The repeat experiment confirmed
our results further. Tre de let n l ne

γ-tumor cell treatment alone failed to protect mice

from lethal challenge. We then reduced the challenge dose of tumor further to 2.5x104 and found
100% protection (Fig. 13E). With the present tumor dose, we found tumors growing later and
becoming palpable from day 21 onwards (Fig. 13D), our immunotherapy regimen was therefore
successful in preventing the growth of tumors at 2.5x104 tumor dose which is nevertheless lethal
as well.
We also examined the role of antibody in the immunotherapy and found high antibody
levels in mice treated with immunotherapy protocol with 1x105, 5x104 tumor dose (Fig. 12D,
12G). Higher antibody levels against tumor however, did not translate into protection against
tumor growth.
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We further examined the role of CD4 and CD8 T cell subsets in immunotherapy protocol.
We observed 75% of mice still protected when depleted of CD4 or CD8 T cells depletion alone
(Fig. 14B). However with combined CD4 and CD8 T cell depletion, 80% of mice were not
protected anymore. This result of ours is similar to the anti-tumor induction model (Fig. 4D)
where combined CD4 and CD8 depletion led to loss of development of protection. We examined
antibody in the immunotherapy model and found the antibody levels dropping after CD4 T cell
depletion but not after CD8 T cell depletion as expected, because of the presence of CD4 T cells
helping antibody production. However, there was no substantial drop in antibody levels in the
group depleted of both CD4 and CD8 T cells. This is similar to what was observed in the antitumor induction model (Fig. 4C), where high antibody levels were found on day 21 in the group
treated with anti-CD4 and anti-CD8, despite loss of protection in all mice. Our present study
however was unable to define the protective mechanism further except showing the involvement
of CD4 and CD8 T cells.
We used the mTg and the lowest dose of 5,000U IL-1 for pre-priming as subclinical preexisting EAT in the immunotherapy model to look for exacerbation (Fig. 15A). We started the
combined model with 5x104 tumor cell dose for challenge. Tumor immunotherapy had no
adverse effect on ongoing thyroiditis induced with mTg and 5,000U IL-1 (Fig. 15C). As we
discussed previously, 5,000U IL-1 as a priming dose is subclinical which can be enhanced with
additional Treg depletion and repeated mTg injections. This pre-priming dose is however
variable as we did not observe enhancement in Fig. 8C, but did in Fig. 11C. In the experiment
with 5x104 tumor dose, no enhancement was observed with 5,000U IL-1 pre-priming dose.
Since 5x104 tumor dose affords only 50% protection, we used 2.5x104 tumor dose to set
up the combined model of immunotherapy and thyroiditis (Fig. 16A). Tumor immune responses
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were unchanged in the presence of ongoing thyroiditis (Fig. 16B). Thyroiditis with mTg and
5,000U IL-1 as the pre-priming dose did not show any exacerbation with the added
immunotherapy regimen (Fig. 16C). This result is in contradiction to what was observed in the
EAT-resistant strain where regressing tumor caused enhanced thyroiditis and vice-versa (103). In
our EAT-susceptible strain, the tumor inoculum is very small and we saw very small palpable
tumors regressing in few mice within the group (2 out of 8). This effect may not be enough to
cause a system wide change in immune response leading to exacerbation of thyroiditis. In EATresistant strain, the DNA vaccine was robust and led to regression of tumors as big as 400 mm2
(103). Similarly in the EAT-resistant strain, the DNA vaccine also had granulocyte monocyte
colony stimulating factor as an adjuvant. That could explain some of the systemic
immunomodulation as well.
Conclusion
In clinical scenarios, systemic immunomodulation or adjuvant therapy is used to boost
immune responses even when antigens are not well defined (107). This emphasis on
immunomodulation creates scenarios where large doses of immunomodulators are administered
for prolonged time periods which leads to increased tumor-specific responses but also creates
problems for the immune system in terms of sequelae such as autoimmunity (107). This
dissertation has explored the interaction of induced anti-tumor immune responses and the
induced autoimmune responses on each to mimic the clinical scenarios of cancer patients
undergoing immunotherapy. Our work demonstrated that the immunotherapeutic protocols used
could have detrimental effects on the subclinical autoimmune diseases whereas the full blown
clinical disease was not exacerbated further. In our mouse model of concurrent induction of
thyroiditis and tumor immunity, we found thyroiditis exacerbation with anti-tumor induction
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regimen, however, anti-tumor immune responses were unchanged. Modeling the pre-existing
autoimmune scenarios, we found that subclinical thyroiditis was enhanced by tumor immune
responses as a consequence of Treg depletion and repeated mTg injections, while autoimmune
thyroiditis and tumor immunity were not affected by each other. Finally, developing an
immunotherapy regimen to prevent tumor growth, we found both autoimmune thyroiditis and
anti-tumor immune responses not influenced by each other.
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Some clinical trials of immunotherapeutic agents against cancers have resulted in the
development of autoimmune sequelae, including autoimmune thyroiditis. It has been suggested
that the immunotherapy resulted in an alteration in the immunoregulatory mechanism(s). Using
ex e

ent l ut

une t y

d t s (EAT),

use

del f H s

t ’s t y

d t s (HT),

the importance of regulatory T cells (Tregs) has been well established; inhibition of Tregs leads
to enhanced thyroiditis with repeated doses of mouse thyroglobulin (mTg) without adjuvant. To
simulate cancer patients, we developed a combined EAT and tumor model in our EATsusceptible mice (CBA/J). In first establishing the tumor model, we found Treg depletion and
irradiated tumor cell immunization necessary for robust anti-tumor immunity. We examined the
anti-tumor induction model further and found memory response where mice withstood secondary
tumor challenge even 28 or 35 days after the primary challenge. Role of CD4 and CD8 T cells
was elucidated and both T cell subsets were observed to mediate protection. Although it was
found that the anti-tumor induction protocol induced tumor antibody, its role in the protection
was unclear in our present studies.
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The anti-tumor induction model was then combined with EAT induction with repeated
injections of mouse thyroglobulin (mTg) without adjuvant. Although prior Treg depletion
enhanced EAT and was necessary for good anti-tumor immunity induction, the concurrent
induction of EAT and anti-tumor immunity had no observable influence on each other. To
determine the influence of tumor immunotherapy on pre-existing autoimmune thyroiditis, we
primed mice with mTg and various doses of interleukin-1β (IL-1β). We tested

us d ses f

IL-1β (20,000, 10,000 nd 5,000U) nd combined it with subsequent anti-tumor and EAT
induction model. We found no mutual influence of either component (either tumor immune
responses or EAT) on each other with various doses tested. However, we found enhanced
thyroiditis in mice tested with the lowest dose of IL-1β, .e. 5,000U, w c w s en nced w t
Treg depletion and repeated mTg injections. In order to examine the influence of regressing
tumor on prior autoimmunity, we developed a tumor immunotherapy model and combined it
with pre-existing EAT induced with mTg and 5,000U IL-1β. Ou

esults d d n t s

w ny

influence of regressing tumor on prior EAT with two doses of tumors tested.
Our studies helped in dissecting out the role of various components in enhancement of
pre-existing autoimmune thyroiditis. Our studies suggest that immunomodulation for tumor
immunotherapy could enhance thyroiditis. Similarly, pre-existing thyroiditis primed with an mTg
and lower IL-1β d se f 5,000U c n be ex ce b ted s well.
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